Literature DB >> 23813556

Glomerular diseases: membranous nephropathy--a modern view.

Claudio Ponticelli1, Richard J Glassock.   

Abstract

Membranous nephropathy (MN) is an autoimmune disease usually associated with a nephrotic syndrome and it may progress to ESRD in the long term. Its etiology is often unknown (idiopathic MN), whereas other cases have a recognizable etiology (secondary MN). In idiopathic MN, the glomerular lesions are mainly caused by autoantibodies against a podocyte membrane protein, the M-type of phospholipase A2 receptor 1. The natural course of idiopathic MN is quite varied with spontaneous complete or partial remissions a relatively common occurrence. Patients with asymptomatic non-nephrotic proteinuria seldom progress and need only conservative management. Those with persistent full-blown nephrotic syndrome and those with declining renal function are candidates for specific treatment with any of several regimens. Cyclical therapy with alternating monthly intravenous and oral glucocorticoids combined with a cytotoxic agent can induce remission and preserve renal function in the long term. Cyclosporine or tacrolimus can induce remission, but relapses are frequent after the drug withdrawal. Mycophenolate mofetil monotherapy seems to be ineffective, but may be beneficial when administered together with steroids. The experience with adrenocorticotropic hormone, natural or synthetic, is limited to a few studies with short-term follow-up, but high rates of remission can be seen after prolonged treatment. A high rate of remission and good tolerance have also been reported with rituximab. Patients with moderate renal insufficiency may also benefit from treatment, but at a price of frequent and serious side effects. With these limitations in mind, idiopathic MN may be considered a treatable disease in many patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23813556      PMCID: PMC3944756          DOI: 10.2215/CJN.04160413

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  53 in total

1.  Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association.

Authors:  C Lefaucheur; B Stengel; D Nochy; P Martel; G S Hill; C Jacquot; J Rossert
Journal:  Kidney Int       Date:  2006-08-30       Impact factor: 10.612

2.  A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy.

Authors:  Claudio Ponticelli; Patrizia Passerini; Maurizio Salvadori; Carlo Manno; Battista Fabio Viola; Sonia Pasquali; Salvatore Mandolfo; Piergiorgio Messa
Journal:  Am J Kidney Dis       Date:  2006-02       Impact factor: 8.860

3.  Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.

Authors:  M Praga; V Barrio; G Fernández Juárez; J Luño
Journal:  Kidney Int       Date:  2007-03-21       Impact factor: 10.612

4.  A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.

Authors:  C Ponticelli; P Altieri; F Scolari; P Passerini; D Roccatello; B Cesana; P Melis; B Valzorio; M Sasdelli; S Pasquali; C Pozzi; G Piccoli; A Lupo; S Segagni; F Antonucci; M Dugo; M Minari; A Scalia; L Pedrini; G Pisano; C Grassi; M Farina; R Bellazzi
Journal:  J Am Soc Nephrol       Date:  1998-03       Impact factor: 10.121

5.  A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.

Authors:  Vivekanand Jha; Anirban Ganguli; Tarun K Saha; Harbir S Kohli; Kamal Sud; Krishan L Gupta; Kusum Joshi; Vinay Sakhuja
Journal:  J Am Soc Nephrol       Date:  2007-05-09       Impact factor: 10.121

6.  Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.

Authors:  Bertrand Dussol; Sophie Morange; Stéphane Burtey; Monica Indreies; Elisabeth Cassuto; Georges Mourad; Emmanuel Villar; Claire Pouteil-Noble; Huseyin Karaaslan; Hélène Sichez; Catherine Lasseur; Yashou Delmas; Marie-Béatrice Nogier; Mohamed Fathallah; Anderson Loundou; Valérie Mayor; Yvon Berland
Journal:  Am J Kidney Dis       Date:  2008-06-30       Impact factor: 8.860

Review 7.  Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum.

Authors:  Richard J Glassock
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

8.  Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy.

Authors:  C Ponticelli; P Zucchelli; E Imbasciati; L Cagnoli; C Pozzi; P Passerini; C Grassi; D Limido; S Pasquali; T Volpini
Journal:  N Engl J Med       Date:  1984-04-12       Impact factor: 91.245

9.  A controlled study of short-term prednisone treatment in adults with membranous nephropathy.

Authors: 
Journal:  N Engl J Med       Date:  1979-12-13       Impact factor: 91.245

10.  Pathologic differentiation between lupus and nonlupus membranous glomerulopathy.

Authors:  J C Jennette; S S Iskandar; F G Dalldorf
Journal:  Kidney Int       Date:  1983-09       Impact factor: 10.612

View more
  69 in total

1.  Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: A meta-analysis of Chinese adults.

Authors:  Zhen-Qiong Li; Man-Li Hu; Chun Zhang; Yu-Mei Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

2.  Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy.

Authors:  George Haddad; Johan M Lorenzen; Hong Ma; Noortje de Haan; Harald Seeger; Christelle Zaghrini; Simone Brandt; Malte Kölling; Urs Wegmann; Bence Kiss; Gábor Pál; Péter Gál; Rudolf P Wüthrich; Manfred Wuhrer; Laurence H Beck; David J Salant; Gérard Lambeau; Andreas D Kistler
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

3.  Analysis of PLA2R1 and HLA-DQA1 sequence variants in Japanese patients with idiopathic and secondary membranous nephropathy.

Authors:  Hajime Kaga; Atsushi Komatsuda; Ayumi Omokawa; Shin Okuyama; Kensuke Mori; Hideki Wakui; Naoto Takahashi
Journal:  Clin Exp Nephrol       Date:  2017-08-28       Impact factor: 2.801

4.  A case of membranous glomerulopathy associated with lung cancer and review of the literature.

Authors:  Aydin Aytekin; Ahmet Ozet; Irem Bilgetekin; Betul Ogut; Aydin Ciltas; Mustafa Benekli
Journal:  Mol Clin Oncol       Date:  2017-06-21

5.  Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.

Authors:  Jan A J G van den Brand; Piero Ruggenenti; Antonietta Chianca; Julia M Hofstra; Annalisa Perna; Barbara Ruggiero; Jack F M Wetzels; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2017-05-09       Impact factor: 10.121

6.  Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis.

Authors:  Lan Huang; Qiao-Rong Dong; Ya-Juan Zhao; Gui-Cai Hu
Journal:  Int Urol Nephrol       Date:  2020-09-17       Impact factor: 2.370

Review 7.  Membranous Nephropathy: A Journey From Bench to Bedside.

Authors:  Jean M Francis; Laurence H Beck; David J Salant
Journal:  Am J Kidney Dis       Date:  2016-04-13       Impact factor: 8.860

8.  Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.

Authors:  Choli Hartono; Miriam Chung; Sheng F Kuo; Surya V Seshan; Thangamani Muthukumar
Journal:  J Nephrol       Date:  2014-01-16       Impact factor: 3.902

Review 9.  Renal Involvement in Idiopathic Inflammatory Myopathies.

Authors:  David Cucchiari; Claudio Angelini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

10.  Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China.

Authors:  Xin Xu; Guobao Wang; Nan Chen; Tao Lu; Sheng Nie; Gang Xu; Ping Zhang; Yang Luo; Yongping Wang; Xiaobin Wang; Joel Schwartz; Jian Geng; Fan Fan Hou
Journal:  J Am Soc Nephrol       Date:  2016-06-30       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.